Brief: Alterity Reports Positive Phase 2 Data for ATH434 in MSA, Shows Clinical Benefit and Biomarker Impact
28/07/2025 12:36
July 28 (Reuters) - Alterity Therapeutics Ltd ATH.AX: ALTERITY THERAPEUTICS REPORTS POSITIVE TOPLINE DATA FROM OPEN-LABEL PHASE 2 CLINICAL TRIAL OF ATH434 IN MULTIPLE SYSTEM ATROPHY ALTERITY THERAPEUTICS LTD - ATH434 WELL-TOLERATED WITH FAVORABLE SAFETY PROFILE ALTERITY THERAPEUTICS LTD - NO SERIOUS ADVERSE EVENTS REPORTED FOR ATH434 ALTERITY THERAPEUTICS LTD - ATH434 SHOWS CLINICAL BENEFIT AND STABILIZES SYMPTOMS Source text: ID:nGNX1dctqJ Further company coverage: ATH.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alterity Therapeutics
See all newsBrief: Alterity Therapeutics Achieves Alignment With U.S. FDA On Pivotal Phase 3 Program For Ath434 In Multiple System Atrophy
Brief: Alterity Therapeutics Receives Positive FDA Feedback On Ath434 Phase 3 Program
Brief: Alterity Therapeutics Says Julian Barbaczy Appointed Non-Exec Chair
Brief: Alterity Therapeutics Raises A$20.0 Million In Strategic Placement
Brief: Alterity Therapeutics Ltd Raises A$20 Million In Capital